Impact of rotavirus vaccine on paediatric rotavirus hospitalisation and intussusception in New Zealand: A retrospective cohort study.

We examined the effect of RotaTeq® vaccination on rotavirus and all-cause gastroenteritis hospitalisation rates using Poisson regression. Adjusted incidence rate ratios controlled for sex, year of birth, ethnicity, socioeconomic deprivation, and district health board area. RESULTS: Significant reductions in the incidence of rotavirus hospitalisation were seen in all age groups, ethnicities, and deprivation following the introduction of RotaTeq®. There was a 92.6% reduction in hospitalisation incidence in the vaccinated cohort (p 
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research

Related Links:

Publication date: November 2019Source: The Lancet Global Health, Volume 7, Issue 11Author(s): Andrew Clark, Jacqueline Tate, Umesh Parashar, Mark Jit, Mateusz Hasso-Agopsowicz, Nicholas Henschke, Benjamin Lopman, Kevin Van Zandvoort, Clint Pecenka, Paul Fine, Colin SandersonSummaryBackgroundInfant rotavirus vaccines have led to substantial reductions in hospital admissions and deaths due to gastroenteritis, but some studies have reported an elevated risk of intussusception, a rare bowel disorder. This analysis aimed to provide evidence on the potential mortality reduction benefits and intussusception risks of current rotav...
Source: The Lancet Global Health - Category: International Medicine & Public Health Source Type: research
Bhaskar Raju, Raunak P Parikh, Volker V Vetter, Shafi KolhapureIndian Journal of Public Health 2019 63(3):243-250 Rotavirus is a leading cause of severe pediatric diarrhea worldwide, with about 199,000 childhood deaths in 2015, of which 90% in low-income countries. India alone accounts for 22% of the global rotavirus gastroenteritis (RVGE)-related deaths among children below 5 years of age. The World Health Organization recommends introducing rotavirus vaccines (RVVs) as a priority in developing countries where high rates of RVGE are observed. To have the desired impact, RVV should be administered the earliest pos...
Source: Indian Journal of Public Health - Category: International Medicine & Public Health Authors: Source Type: research
CONCLUSIONS: At two years of follow-up, RotaSIIL was found to be safe. TRIAL REGISTRATION: ClinicalTrials.gov: NCT02145000. PMID: 29752026 [PubMed - as supplied by publisher]
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research
ConclusionsThe vaccine-prevented RVGE hospitalizations and deaths (benefit) greatly outweigh the excess potentially vaccination-related cases of intussusception (risk), indicating a favorable benefit –risk balance for Rotarix in France.
Source: BioDrugs - Category: Drugs & Pharmacology Source Type: research
AbstractRotaTeq® is a three-dose, pentavalent, human-bovine reassortment vaccine, indicated for the prevention of rotavirus gastroenteritis (RVGE) in infants aged 6 –32 weeks in the EU. The vaccine solution is given orally and can be administered with a number of common childhood vaccines. In the pivotal REST study, RotaTeq® showed high protective efficacy with respect to reductions in the RVGE incidence and associated hospitalizations or emergency department visits. The effectiveness and impact of the vaccine against RVGE-related healthcare use were demonstrated in several real-world studies. RotaTeq&re...
Source: Drugs and Therapy Perspectives - Category: Drugs & Pharmacology Source Type: research
Conclusion: The benefit-risk ratio in France is similar to that of other European countries. PMID: 29258644 [PubMed - in process]
Source: Euro Surveill - Category: Infectious Diseases Authors: Tags: Euro Surveill Source Type: research
Introduction: Rotavirus is a leading cause of acute gastroenteritis among Taiwanese children. Two globally licensed rotavirus vaccines recommended for inclusion in routine immunization programs that have been available for private market use in Taiwan since 2006 have been associated with a low risk of intussusception in postmarketing studies conducted in several countries. Our objective was to examine trends and characteristics of intussusception hospitalizations in Taiwan among children
Source: The Pediatric Infectious Disease Journal - Category: Infectious Diseases Tags: Vaccine Reports Source Type: research
Conclusions These results provide encouraging initial evidence of the public health benefit, including to the unimmunised population, of the RV vaccination programme in the UK.
Source: Archives of Disease in Childhood - Category: Pediatrics Authors: Tags: Infection (gastroenterology), Immunology (including allergy), Drugs: infectious diseases, Foodborne infections, Vaccination / immunisation Original article Source Type: research
Conclusions The benefit–risk balance for Rotarix™ is favorable in Japan. From a public health perspective, the benefits in terms of prevented RVGE hospitalizations and deaths for the vaccinated population far exceed the estimated risks due to intussusception.
Source: Drug Safety - Category: Drugs & Pharmacology Source Type: research
Conclusions: In Sicily from 2003 to 2012 hospitalizations due to intestinal invagination were higher among children aged 0–11 months with observed rates similar to other European countries. Regional baseline data analysis of intussusception among 0–59 children is recognized as an evidence-based public health strategy by international health authorities. Indeed, this strategy is necessary to compare any post-licensure age or sex-related change in intussusception trend after universal rotavirus vaccination introduction.
Source: Italian Journal of Pediatrics - Category: Pediatrics Authors: Source Type: research
More News: Allergy & Immunology | Children | Gastroenteritis | Gastroenterology | Intussusception | New Zealand Health | Pediatrics | Rotavirus | Rotavirus Vaccine | Science | Study | Vaccines